Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
T
TC Biopharm (Holdings) PLC. Stock Analysis TCBPY
United States Health Care Nano Cap TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 39 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified GD-T cell product line - phase IIb/III pivotal trial in treatment of AML using its allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product candidate, OmnImmune is an unmodified allogeneic GD-T cell product, being initially used for the treatment of AML. Its pre-clinical stage program is focused on developing CAR-modified allogeneic GD-T cell products targeting solid and hematological indications. The company has an Israeli patent and Japanese patent applications covering the method of preparing and using GD-T cells in the allogeneic treatment of subjects suffering from viral, fungal and protozoal infections or cancer.
Read More TC Biopharm (Holdings) PLC (TCBPY) Chart
Key Statistics of TC Biopharm (Holdings) PLC (TCBPY)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.01Volume
2001.00P/E Ratio (TTM)
-52 Week Range
Market Cap
3507.00Avg. Volume
8172.13Dividend Yield
-Financial Metrics & Statements of TC Biopharm (Holdings) PLC (TCBPY)
FAQ's for TC Biopharm (Holdings) PLC (TCBPY)
- According to Musaffa’s Shariah screening methodology, TC Biopharm (Holdings) PLC (TCBPY) is currently classified as NOT COVERED as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes TC Biopharm (Holdings) PLC using these criteria to determine its compliance status.
- Muslim investors may consider investing in TC Biopharm (Holdings) PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of TC Biopharm (Holdings) PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of TC Biopharm (Holdings) PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of TC Biopharm (Holdings) PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.